#United States #New York #Faruqi & Faruqi #ALDX #Aldeyra Therapeutics

Important Update for Aldeyra Therapeutics Investors

As the deadline for potential investors to engage in a class action lawsuit against Aldeyra Therapeutics approaches, law firm Faruqi & Faruqi, LLP is urging affected individuals to act promptly. The deadline for becoming a lead plaintiff in this case is set for May 29, 2026.

Background of the Case

Faruqi & Faruqi is known for its extensive experience in securities law, having successfully represented numerous investors since its establishment in 1995. In the current situation, the firm is investigating claims against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) regarding significant failures in disclosing crucial information and providing reliable data about one of its key drug candidates, reproxalap.

Key Allegations

The lawsuit accuses the company and its executives of breaching federal securities laws due to the following reasons:
1. Inconsistent Clinical Trial Results: The clinical trials for reproxalap yielded conflicting results.
2. Misleading Statements: These inconsistencies cast doubt on the positive claims made by the company regarding the drug's effectiveness in treating dry eye disease. Consequently, the information presented about Aldeyra's overall business operations and future prospects was not only misleading but also lacked substantive support.
3. Investor Impact: When the facts became public, stemming from a Complete Response Letter issued by the FDA on March 17, 2026, which rejected Aldeyra's New Drug Application due to insufficient evidence of efficacy, investors experienced notable financial losses, with stock prices plummeting by nearly 71% following the announcement.

Call to Action

Faruqi & Faruqi encourages anyone who purchased Aldeyra securities from November 3, 2023, to March 16, 2026, to contact them for a consultation regarding their legal rights. The firm has extensive resources to assist investors in navigating their positions during this tumultuous time.

Your Rights as an Investor

Investors who wish to take action may move the Court to appoint them as lead plaintiffs—individuals who represent the collective interests of all affected shareholders. Alternatively, investors can choose not to take an active role and remain part of the class without impacting their rights to any potential recovery.

Contact Information

For further details or to discuss potential claims, affected investors can reach out to Faruqi & Faruqi partner James (Josh) Wilson via phone at 877-247-4292 or 212-983-9330 (Ext. 1310). You can also visit www.faruqilaw.com/ALDX for more information about the ongoing litigation and your options.

Conclusion

As the deadline draws near, it is imperative for Aldeyra investors to remain vigilant and informed. The stakes are high, and your rights as an investor deserve the utmost attention. Act now to ensure your voice and interests are represented.

• ---

Note: This article is intended for informational purposes only and does not constitute legal advice.